Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials

Gil Yosipovitch; Jennifer Soung; Jonathan Weiss; Elisa Muscianisi; Xiangyi Meng; Isabelle Gilloteau; Boni E. Elewski

doi:10.2340/00015555-3195

Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials

Gil Yosipovitch, Jennifer Soung, Jonathan Weiss, Elisa Muscianisi, Xiangyi Meng, Isabelle Gilloteau, Boni E. Elewski

Dermatology & Cutaneous Surgery

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	820-821
Number of pages	2
Journal	Acta dermato-venereologica
Volume	99
Issue number	9
DOIs	https://doi.org/10.2340/00015555-3195
State	Published - Jul 2019

ASJC Scopus subject areas

Dermatology

Access to Document

10.2340/00015555-3195

Cite this

Yosipovitch, G., Soung, J., Weiss, J., Muscianisi, E., Meng, X., Gilloteau, I., & Elewski, B. E. (2019). Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials. Acta dermato-venereologica, 99(9), 820-821. https://doi.org/10.2340/00015555-3195

Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis : Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials. / Yosipovitch, Gil; Soung, Jennifer; Weiss, Jonathan; Muscianisi, Elisa; Meng, Xiangyi; Gilloteau, Isabelle; Elewski, Boni E.

In: Acta dermato-venereologica, Vol. 99, No. 9, 07.2019, p. 820-821.

Research output: Contribution to journal › Comment/debate › peer-review

Yosipovitch, G, Soung, J, Weiss, J, Muscianisi, E, Meng, X, Gilloteau, I & Elewski, BE 2019, 'Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials', Acta dermato-venereologica, vol. 99, no. 9, pp. 820-821. https://doi.org/10.2340/00015555-3195

Yosipovitch, Gil ; Soung, Jennifer ; Weiss, Jonathan ; Muscianisi, Elisa ; Meng, Xiangyi ; Gilloteau, Isabelle ; Elewski, Boni E. / Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis : Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials. In: Acta dermato-venereologica. 2019 ; Vol. 99, No. 9. pp. 820-821.

@article{c9ca427af6c74aebae7e704a90ea62b2,

title = "Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials",

author = "Gil Yosipovitch and Jennifer Soung and Jonathan Weiss and Elisa Muscianisi and Xiangyi Meng and Isabelle Gilloteau and Elewski, {Boni E.}",

note = "Funding Information: Support for thirdparty writing assistance for this manuscript, furnished by Eric Deutsch, PhD, CMPP, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Conflicts of interest: GY has received grants from Sun Pharma and Pfizer outside the submitted work; honoraria from Bayer, Eli Lilly, Galderma, Menlo, Novartis, Opko, Pfizer, Regeneron, Sanofi, Sienna, Trevi, and UCB; and nonfinancial support from Novartis during the conduct of the study. JS has received speaker honoraria from AbbVie, Actelion, Amgen, Celgene, Lilly, the National Psoriasis Foundation, Novartis, Ortho Dermatologics, and Regeneron; consulting/advisory board honoraria from Leo Pharma, Lilly, and Novartis; and grant/research funding from AbbVie, Actavis, Actelion, Allergan, Boehringer Ingelheim, Cassiopea, Dr. Reddy{\textquoteright}s, Galderma, GSK, Janssen, Kadmon, Leo Pharma, Menlo, Novan, Novartis, Ortho Dermatologics, Pfizer, and UCB. JW has received speaker honoraria from AbbVie and Ortho Dermatologics; consulting/advisory board honoraria from Aclaris, Foamix, Galderma, Leo Pharma, and Valeant (Ortho Dermatologics); and grant/research funding support to their institution from AbbVie, Aclaris, Endo International, Foamix, Galderma, Leo Pharma, Moberg Pharma North America, Novartis, Promius Pharma, and Valeant (Ortho Dermatologics). EM, XM, and IG are employees of Novartis. B. EE has received grant/research funding to their university from AbbVie, Boehringer Ingelheim, Celgene, Incyte, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and Valeant (Ortho Dermatologics); and consulting fees from Boehringer Ingelheim, Celgene, Leo Pharma, Lilly, Novartis, Pfizer, Sun Pharma, and Valeant (Ortho Dermatologics).",

year = "2019",

month = jul,

doi = "10.2340/00015555-3195",

language = "English (US)",

volume = "99",

pages = "820--821",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Society for the Publication of Acta Dermato-Venereologica",

number = "9",

}

TY - JOUR

T1 - Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis

T2 - Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials

AU - Yosipovitch, Gil

AU - Soung, Jennifer

AU - Weiss, Jonathan

AU - Muscianisi, Elisa

AU - Meng, Xiangyi

AU - Gilloteau, Isabelle

AU - Elewski, Boni E.

N1 - Funding Information: Support for thirdparty writing assistance for this manuscript, furnished by Eric Deutsch, PhD, CMPP, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Conflicts of interest: GY has received grants from Sun Pharma and Pfizer outside the submitted work; honoraria from Bayer, Eli Lilly, Galderma, Menlo, Novartis, Opko, Pfizer, Regeneron, Sanofi, Sienna, Trevi, and UCB; and nonfinancial support from Novartis during the conduct of the study. JS has received speaker honoraria from AbbVie, Actelion, Amgen, Celgene, Lilly, the National Psoriasis Foundation, Novartis, Ortho Dermatologics, and Regeneron; consulting/advisory board honoraria from Leo Pharma, Lilly, and Novartis; and grant/research funding from AbbVie, Actavis, Actelion, Allergan, Boehringer Ingelheim, Cassiopea, Dr. Reddy’s, Galderma, GSK, Janssen, Kadmon, Leo Pharma, Menlo, Novan, Novartis, Ortho Dermatologics, Pfizer, and UCB. JW has received speaker honoraria from AbbVie and Ortho Dermatologics; consulting/advisory board honoraria from Aclaris, Foamix, Galderma, Leo Pharma, and Valeant (Ortho Dermatologics); and grant/research funding support to their institution from AbbVie, Aclaris, Endo International, Foamix, Galderma, Leo Pharma, Moberg Pharma North America, Novartis, Promius Pharma, and Valeant (Ortho Dermatologics). EM, XM, and IG are employees of Novartis. B. EE has received grant/research funding to their university from AbbVie, Boehringer Ingelheim, Celgene, Incyte, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and Valeant (Ortho Dermatologics); and consulting fees from Boehringer Ingelheim, Celgene, Leo Pharma, Lilly, Novartis, Pfizer, Sun Pharma, and Valeant (Ortho Dermatologics).

PY - 2019/7

Y1 - 2019/7

UR - http://www.scopus.com/inward/record.url?scp=85069889535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069889535&partnerID=8YFLogxK

U2 - 10.2340/00015555-3195

DO - 10.2340/00015555-3195

M3 - Comment/debate

C2 - 31017248

AN - SCOPUS:85069889535

VL - 99

SP - 820

EP - 821

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 9

ER -